Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 17:01 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications
NCT02213887 · University of British Columbia · PHASE4 · withdrawn · last registry update 2021-10-08 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Unable to recruit participants” | – | Registry record, University of British Columbia |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ATP4A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-07-07Phase 3 first posted: Onconic Therapeutics Inc., JP-1366 20mg + Lansoprazole 30mg (NCT05448001)
- 2022-07-05Phase 3 first posted: Onconic Therapeutics Inc., JP-1366 20mg + Esomeprazole 40mg (NCT05443984)
- 2022-03-04Phase 3 first posted: AstraZeneca, Nexium 20mg + Nexium 10mg (NCT05267613)
- 2022-02-07Phase 3 first posted: Alexandria University, Vonoprazan fumarate (Vonaspire) + Pantoprazole 40mg (NCT05227833)
- 2021-07-16Phase 3 first posted: Norfolk and Norwich University Hospitals NHS Foundation Trust, Lansoprazole (NCT04965298)
- 2021-04-12Phase 3 first posted: HK inno.N Corporation, Lansoprazole 15 mg + Tegoprazan 25 mg (NCT04840550)
- 2021-03-05Phase 3 first posted: Daewoong Pharmaceutical Co. LTD., DWP14012 20mg + Lansoprazole 15 mg (NCT04784910)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision